You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Immune Checkpoint Inhibitor Toxicity Management Clinical Practice Guideline

Version: 1 Mar 2018
Type of Content: Guidelines & Advice, Clinical
Document Status: Current

Guideline Objective

Immune checkpoint inhibitor medications are associated with unique immune-related adverse effects (irAEs) that can range from bothersome to life-threatening. Symptoms vary in their onset time, can progress quickly, and may occur months after treatment discontinuation. Early identification of irARs and appropriate management can improve patients’ quality of life and safety.

The objective of this guideline is to provide user-friendly guidance for the management of irAEs. It contains the following:

  • A description of irAEs associated with immune checkpoint inhibitor medications.
  • Practical guidance on the general management of irAEs.
  • Detailed algorithms that describe the assessment and management of ten specific irAEs.
  • General considerations for patients on immune checkpoint inhibitor medications.


Intended Guideline Users

All clinicians involved in the care of cancer patients who are receiving immune checkpoint inhibitor medications.

Guideline-Based Clinical Tools